3-甲氧基甲氧基吡啶 | 81245-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-甲氧基甲氧基吡啶
• 英文名称: 3-(methoxymethoxy)pyridine
• 英文别名: 3-(methoxymethyloxy)pyridine
• CAS: 81245-25-2
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: UEHRAKHRJFMBOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲氧基甲氧基吡啶 在 正丁基锂 、 偶氮二甲酸二异丙酯 、 5%-palladium/activated carbon 、 氢气 、 potassium carbonate 、 三苯基膦 、 copper(I) bromide 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.33h， 生成 4-[3-[2-(4-Chlorophenoxy)pyridin-3-yl]oxypropyl]pyridin-3-ol
  参考文献：
  名称：

  Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors

  摘要：

  A series of 2,3-disubstituted pyridines were synthesized as potential non-emetic PDE4 inhibitors. To decrease brain exposure and minimize emesis, we modified the lipophilic moiety of a series of emetic PDE4 inhibitors and found that introduction of a hydroxy group into the pyridine moiety of the side chain led to non-emetic compounds with preserved PDE4 inhibitory activity. Following optimization at the phenoxy group, we identified compound 1 as a potent non-emetic PDE4 inhibitor. Compound 1 showed significant efficacy in an animal model of asthma without inducing emesis. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.052
• 作为产物：
  描述：

  3-羟基吡啶 、 氯甲基甲基醚 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以66%的产率得到3-甲氧基甲氧基吡啶
  参考文献：
  名称：

  炔丙基缩醛制备双环乙烯基杂环的新方法

  摘要：

  本文描述了进一步的研究，以炔丙基缩醛与芳基锂的分子内碳甲酸酯化反应生成2-乙烯基苯并呋喃和3-乙烯基呋喃吡啶。尝试将级联扩展至[4.4.0]双核杂环的尝试取得了有限的成功。使用钯诱导的环化/氢化物捕获方法已经开发了进入这种环系统的另一种两步方法。还公开了从简单的苯甲酰胺制异喹啉酮的新途径。

  DOI：

  10.1021/jo048794d

文献信息

• [EN] INHIBITORS OF THE KYNURENINE PATHWAY<br/>[FR] INHIBITEURS DE LA VOIE DE LA KYNURÉNINE
  申请人：CURADEV PHARMA PRIVATE LTD

  公开号：WO2014186035A1

  公开（公告）日：2014-11-20

  The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.

  本申请提供了吲哚胺2,3-双加氧酶-1和/或吲哚胺2,3-双加氧酶-2和/或色氨酸2,3-双加氧酶的新型抑制剂，以及它们的代谢物，以及药用可接受的盐或前药。还提供了制备这些化合物的方法。治疗有效量的一个或多个公式(I)的化合物可用于治疗由于色氨酸途径失调导致的疾病。公式(I)的化合物通过抑制吲哚胺2,3-双加氧酶-1和/或吲哚胺2,3-双加氧酶-2和/或色氨酸2,3-双加氧酶的酶活性或表达起作用。
• Enantioselective total synthesis of the antifungal dilactone, UK-2A: The determination of the relative and absolute configurations
  作者：Masanao Shimano、Tetsuo Shibata、Noriyuki Kamei

  DOI：10.1016/s0040-4039(98)00796-5

  日期：1998.6

  The synthesis of the antifungal dilactone, UK-2A, is described. In addition to providing a workable synthetic route to this potent antifungal antibiotic, this has allowed us to determine the assignment of the relative and absolute configurations in the nine-membered ring.

  描述了抗真菌双内酯UK-2A的合成。除了为这种有效的抗真菌抗生素提供可行的合成途径外，这还使我们能够确定九元环中相对构型和绝对构型的分配。
• MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME
  申请人：Hoveyda Hamid

  公开号：US20080194672A1

  公开（公告）日：2008-08-14

  The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，可以作为生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、骨骼疾病、遗传疾病、过度增生性疾病和炎症性疾病。
• MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS
  申请人：Marsault Eric

  公开号：US20100093720A1

  公开（公告）日：2010-04-15

  The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

  本发明提供了与胃动素受体及其亚型、异构体和/或变体结合和/或是功能调节剂的构象定义明确的大环化合物。这些大环化合物至少具有足够的药理特性，可用作治疗一系列疾病指示的治疗药物。特别是，这些化合物对于治疗和预防以高胃动素血症和/或胃肠道高蠕动性为特征的疾病非常有用，包括但不限于腹泻、癌症治疗相关腹泻、癌症诱导腹泻、化疗诱导腹泻、放射性肠炎、放射性腹泻、压力诱导腹泻、慢性腹泻、艾滋病相关腹泻、C. difficile相关腹泻、旅行者腹泻、移植物宿主病引起的腹泻、其他类型的腹泻、消化不良、肠易激综合征、化疗诱导的恶心和呕吐（呕吐）以及术后恶心和呕吐和功能性胃肠道疾病。此外，这些化合物对于治疗以胃或肠道吸收不良为特征的疾病和疾病也具有用途，例如短肠综合征、乳糜泻和虚弱。这些化合物还可用于治疗胃肠道炎症性疾病和疾病，如炎症性肠病、溃疡性结肠炎、克罗恩病和胰腺炎。因此，本发明还提供了治疗此类疾病的方法和包括本发明化合物的药物组合物。
• Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates
  作者：Armin Thalhammer、Jasmin Mecinović、Christoph Loenarz、Anthony Tumber、Nathan R. Rose、Tom D. Heightman、Christopher J. Schofield

  DOI：10.1039/c0ob00592d

  日期：——

  Based on structural analysis of the human 2-oxoglutarate (2OG) dependent JMJD2 histoneNε-methyl lysyl demethylase family, 3-substituted pyridine 2,4-dicarboxylic acids were identified as potential inhibitors with possible selectivity over other human 2OG oxygenases. Microwave-assisted palladium-catalysed cross coupling methodology was developed to install a diverse set of substituents on the sterically demanding C-3 position of a pyridine 2,4-dicarboxylate scaffold. The subsequently prepared di-acids were tested for in vitro inhibition of the histone demethylase JMJD2E and another human 2OG oxygenase, prolyl-hydroxylase domain isoform 2 (PHD2, EGLN1). A subset of substitution patterns yielded inhibitors with selectivity for JMJD2E over PHD2, demonstrating that structure-based inhibitor design can enable selective inhibition of histone demethylases over related human 2OG oxygenases.

  基于对人类依赖2-氧戊二酸（2OG）的JMJD2组蛋白Nε-甲基赖氨酸去甲基酶家族的结构分析，发现3-取代的吡啶-2,4-二羧酸为潜在抑制剂，可能对其他人类2OG氧化酶具有选择性。开发了微波辅助钯催化的交叉偶联方法学，用于在空间位阻较大的吡啶-2,4-二羧酸盐骨架的C-3位上安装一系列不同的取代基。随后制备的二羧酸被测试用于体外抑制组蛋白去甲基酶JMJD2E和另一种人类2OG氧化酶，脯氨酰羟化酶结构域同工型2（PHD2，EGLN1）。部分取代模式产生的抑制剂对JMJD2E具有选择性，表明基于结构的抑制剂设计可以实现对组蛋白去甲基酶相较于相关人类2OG氧化酶的选择性抑制。